Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development
Fusion Pharmaceuticals Inc. , a
clinical-stage oncology company focused on developing next-generation
radiopharmaceuticals as precision medicines,
announced its nomination of the first targeted alpha therapy (TAT) candidate
under a collaboration agreement with AstraZeneca Both companies will jointly develop the novel
TAT through its Phase 1 study, which utilizes the Fusion's Fast-Clear™ linker
technology to radiolabel an AstraZeneca-owned bispecific antibody with the
alpha-emitting isotope, actinium-225.
Under the terms of the previously announced
collaboration agreement, Fusion will be operationally responsible for
preclinical development through first-in-human studies, while AstraZeneca will
be responsible for subsequent clinical development. The companies will share
costs equally through clinical development. IND enabling studies, are ongoing.
To
read more please visit:
Source: Fusion